Tuesday , November 21 2017
Home / Conditions / Type 1 Diabetes / International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #2: Classification of Diabetes Mellitus and Other Categories of Glucose Intolerance Part 2 of 6

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #2: Classification of Diabetes Mellitus and Other Categories of Glucose Intolerance Part 2 of 6

DeFronzoCoverDIABETES TYPES

Type 1 process

Type 1 indicates the processes of β-cell destruction that may ultimately lead to diabetes in which insulin is required for survival in order to prevent the development of ketoacidosis, coma, and death.This category comprises:

  • Immune-mediated diabetes mellitus: This is the classical form of type 1 diabetes, which can occur at any age, and results from a cell-mediated autoimmune destruction of the pancreatic β cells. The type 1 process is characterized by the presence ofICA, anti-GAD, islet antigen 2 (IA2) or insulin autoantibodies which identify the autoimmune process associated with β-cell destruction [9]. Other autoimmune disorders such as Grave’s disease, Hashimoto’s thyroiditis and Addison’s disease may be associated with type 1 diabetes mellitus [9].

The rate of β-cell destruction is quite variable, typically being rapid in children and slower in adults. Typically, type 1 diabetes requires insulin therapy from the time of presentation in both adults and children, but a slowly progressive form, latent autoimmune diabetes in adults (LADA), is well described [8]. Blood glucose in LADA can initially be controlled by lifestyle change and oral hypoglycemic agents, and may therefore masquerade as type 2 diabetes. However, in comparison to the typical patient with type 2 diabetes, LADA patients are leaner and progress much more rapidly to requiring insulin. Importantly, markers of autoimmunity (most commonly anti-GAD antibodies) are present, and therefore LADA falls within type 1 autoimmune diabetes.

  • Idiopathic:There are some forms of type 1 diabetes which have no known etiology, and no evidence of autoimmunity. Some of these patients have permanent insulinopenia and are prone to ketoacidosis [10].This form is more common among individuals of African and Asian origin [11].

Type 2 process

Type 2 diabetes is the commonest form of diabetes and is characterized by disorders of insulin resistance and insulin secretion, either of which may be the predominant feature. Both are usually present at the time when diabetes is clinically manifest. Insulin levels may be normal or even elevated at the time when diabetes is diagnosed. However, in the setting of insulin resistance, these levels are inadequate to maintain normoglycemia. This relative insulin deficiency is what differentiates diabetic insulin-resistant individuals from normoglycemic insulin-resistant individuals. Indeed, it is noteworthy that, to date, the majority of the genes that have been associated with type 2 diabetes are related to insulin secretion, and not to insulin resistance [12].

At least initially, and often throughout their lifetime, these individuals do not need insulin treatment to survive [13]. Type 2 diabetes is frequently asymptomatic and undiagnosed for many years because the hyperglycemia is often not severe enough to provoke noticeable symptoms [14]. Nevertheless, such patients are at increased risk of developing macrovascular and microvascular complications. Type 2 diabetes is a very heterogeneous disorder and there are certainly many different causes of this form of diabetes. However, it is likely that the number of patients placed in this category will decrease in the future as identification of specific pathogenic processes and genetic defects permit better differentiation and a more definitive classification. Although the specific etiologies of type 2 diabetes are not known, autoimmune destruction of the pancreas does not occur and patients do not have any of the other specific causes of diabetes listed in Table 1.2.

ITDMTable1.2aITDMTable1.2b

Most patients with the type 2 process of diabetes are overweight or obese, and obesity itself causes insulin resistance. Many of those not obese by traditional criteria, for example body mass index, may have an increased percentage of body fat distributed predominantly in the abdominal region [13]. Ketoacidosis seldom occurs in type 2 diabetes and when seen, it usually arises in association with the stress of another illness such as infection. Ketosis-prone atypical diabetes, also referred to as ketosis-prone type 2 diabetes is characterized by presentation with severe hyperglycemia and ketoacidosis requiring immediate insulin therapy [15]. More than 50% of these individuals will revert to an insulin-free near-normoglycemia within weeks or months with multiorgan insulin resistance not dissimilar to type 2 diabetes [16]. This condition is commonly found in sub-Saharan Africa and African migrants and is referred to as “Flatbush diabetes”[17].

The risk of developing type 2 diabetes increases with age, obesity, and lack of physical activity. It occurs more frequently in women with prior GDM, in those with hypertension or dyslipidemia, and its frequency varies between different ethnic subgroups [7]. Type 2 diabetes is often associated with strong familial, likely genetic, predisposition but the genetics of type 2 diabetes are quite complex and not clearly defined [18]. Some patients who present a clinical picture consistent with type 2 diabetes have been shown to have antibodies similar to those found in type 1 diabetes.

Although diagnosis in most patients with type 2 diabetes is made in adult years, the disease is now increasingly seen in adolescents and even children, especially in a background of high obesity prevalence. At presentation, ketosis or even ketoacidosis, may occur in this younger age group and insulin is often required in the initial management. However, once the acute metabolic disturbance is rectified, insulin can often be withdrawn, and glycemic control achieved with lifestyle measures and oral pharmacotherapy.

References

  1. World Health Organization (WHO): Diabetes Mellitus. Report of a WHO Expert Committee. Technical Report Series 310. Geneva: WHO, 1965.
  2. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039–1057.
  3. World Health Organization: WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. Geneva: WHO, 1980.
  4. World Health Organization: Diabetes mellitus. Report of a WHO Study Group. Technical Report Series 727. Geneva: WHO, 1985, p. 727.
  5. American Diabetes Association (ADA): Diagnosis and classification of diabetes mellitius. Diabetes Care 2011;34(S1):S62–69.
  6. Kuzuya T, Matsuda A: Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. Diabetes Care 1997;20:219–220.
  7. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus.Geneva:WHO, 1999. Report No.WHO/NCD/NCS/99.2.
  8. Tuomi T, Groop L, Zimmet P, et al.: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin dependent onset of disease. Diabetes 1993;42:359–362.
  9. Atkinson M, Maclaren N: The pathogenesis of insulin-dependent diabetes mellitus. New England Journal of Medicine 1994;331:1428–1436.
  10. McLarty D, Atharde I, Bottazzo G, et al.: Islet cell antibodies are not specifically associated with insulin-dependent diabetes in Tanzanian Africans. Diabetes Research and Clinical Practice 1990;9:219–224.
  11. Ahrén B, Corrigan C: Intermittant need for insulin in a subgroup of diabetic patients in Tanzania. Diabetic Medicine 1984;2:262–264.
  12. Billings LK, Florez JC: The genetics of type 2 diabetes: what have we learned from GWAS? Annals of the New York Academy of Sciences 2010;1212:59–77.
  13. Kissebah A, Vydelingum N, Murray R, et al.: Relation of body fat distribution to metabolic complications of obesity. Journal of Clinical Endocrinology & Metabolism 1982;54:254–260.
  14. Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992; 15:815–819.
  15. Gill GV, Mbanya JC, Ramaiya KL, Tesfaye S: A sub-Saharan African perspective of diabetes. Diabetologia 2009;52:8–16.
  16. Sobngwi E, Mauvais-Jarvis F, Vexiau P, et al.: Diabetes in Africans. Part 2: Ketosis-prone atypical diabetes mellitus. Diabetes & Metabolism 2002;28:5–12.
  17. Banerji M, Chaiken R, Huey H, et al.: GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of HLA DR3 and DR4. Flatbush diabetes. Diabetes 1994;13:741–745.
  18. Meigs JB, Shrader P, Sullivan LM, et al.: Genotype score in addition to common risk factors for prediction of type 2 diabetes. New England Journal of Medicine 2008;359:2208–2219.
  19. Hattersley A, Bruining J, Shield J, et al.: ISPAD Clinical Practice Consensus Guidelines 2006–2007. The diagnosis and management of monogenic diabetes in children. Pediatric Diabetes 2006;7:352–360.
  20. Vionnet N, Stoffel M, Takeda J, et al.: Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 1992;356:721–722.
  21. Murphy R, Ellard S, Hattersley AT: Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nature Clinical Practice Endocrinology and Metabolism 2008;4:200–213.
  22. Spyer G, Macleod KM, Shepherd M, et al.: Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Diabetic Medicine 2009;26:14–18.
  23. Stride A, Vaxillaire M, Tuomi T, et al.: The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 2002;45:427–435.
  24. Hattersley A, Bruining J, Shield J, et al.: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric Diabetes 2009;10(Suppl 12):33–42.
  25. Iafusco D, Stazi MA, Cotichini R, et al.: Permanent diabetes mellitus in the first year of life. Diabetologia 2002;45:798–804.
  26. Ellard S, Flanagan SE, Girard CA, et al.: Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. American Journal of Human Genetics 2007;81:375–382.
  27. Rigoli L, Di Bella C: Wolfram syndrome 1 and Wolfram syndrome 2. Current Opinion in Pediatrics 2012;24:512–517.
  28. Maassen JA, Kadowaki T: Maternally inherited diabetes and deafness: a new diabetes subtype. Diabetologia 1996;39:375–382.
  29. Robbins DC, Shoelson SE, Rubenstein AH, Tager HS: Familial hyperproinsulinemia. Two cohorts secreting indistinguishable type II intermediates of proinsulin conversion. Journal of Clinical Investigation 1984;73:714–719.
  30. Haneda M, Polonsky KS, Bergenstal RM, et al.: Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. New England Journal of Medicine 1984;310:1288–1294.
  31. Johns DR: Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. New England Journal of Medicine 1995;333:638–644.
  32. Semple RK, Savage DB, Cochran EK, et al.: Genetic syndromes of severe insulin resistance. Endocrine Reviews 2011;32:498–514.
  33. Gullo L, Pezzilli R, Morselli-Labate AM: Diabetes and the risk of pancreatic cancer. New England Journal of Medicine 1994;331: 81–84.
  34. Permert J, Larsson J, Westermark GT, et al.: Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. New England Journal of Medicine 1994;330:313–318.
  35. Utzschneider KM, Kowdley KV: Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice. Nature Reviews Endocrinology 2010;6:26–33.
  36. Yajnik CS, Shelgikar KM, Naik SS, et al.: The ketoacidosis-resistance in fibro-calculous-pancreatic-diabetes. Diabetes Research and Clinical Practice 1992;15:149–156.
  37. Krejs GJ,Orci L,Conlon JM, et al.: Somatostatinoma syndrome. Biochemical, morphologic and clinical features. New England Journal of Medicine 1979;301:285–292.
  38. Pandit MK, Burke J, Gustafson AB, et al.: Drug-induced disorders of glucose tolerance. Annals of Internal Medicine 1993;118: 529–540.
  39. Miller LV, Stokes JD, Silpipat C: Diabetes mellitus and autonomic dysfunction after vacor rodenticide ingestion. Diabetes Care 1978; 1:73–76.
  40. Assan R, Perronne C,Assan D, et al.: Pentamidine-induced derangements of glucose homeostasis. Diabetes Care 1995;18:47–55.
  41. Madziarska K: New-onset posttransplant diabetes mellitus begins in the dialysis period. Journal of Renal Nutrition 2012;22:162–165.
  42. Drachenberg CB, Klassen DK, Weir MR, et al.: Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999;68:396–402.
  43. Penfornis A, Kury-Paulin S: Immunosuppressive drug-induced diabetes. Diabetes & Metabolism 2006;32:539–546.
  44. Fabris P, Betterle C, Floreani A, et al.: Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992;340:548.
  45. Sattar N, Preiss D, Murray HM, et al.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–742.
  46. Preiss D, Seshasai SR, Welsh P, et al.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556–2564.
  47. Wang KL, Liu CJ, Chao TF, et al.: Statins, risk of diabetes, and implications on outcomes in the general population. Journal of the American College of Cardiology 2012;60(14):1231–1238.
  48. Guo JJ, Keck PE, Jr,, Corey-Lisle PK, et al.: Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. Journal of Clinical Psychiatry 2006;67:1055–1061.
  49. Kalra S, Kalra B, Agrawal N, Unnikrishnan A: Understanding diabetes in patients with HIV/AIDS. Diabetology and Metabolic Syndrome 2011;3:2.
  50. De Wit S, Sabin CA, Weber R, et al.: Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008;31:1224–1229.
  51. Fleischman A, Johnsen S, Systrom DM, et al.: Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. American Journal of Physiology—Endocrinology and Metabolism 2007;292: E1666–1673.
  52. Lansang MC, Hustak LK: Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleveland Clinical Journal of Medicine 2011;78:748–756.
  53. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. New England Journal of Medicine 2005;353:1711–1723.
  54. van Raalte DH, Nofrate V, Bunck MC, et al.:Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthymen. European Journal of Endocrinology 2010;162:729–735.
  55. Forrest JM, Menser MA, Burgess JA: High frequency of diabetes mellitus in young adults with congenital rubella. Lancet 1971; 2:332–334.
  56. King ML, Bidwell D, Shaikh A, et al.: Coxsackie-B-virus-specific IgM responses in children with insulin-dependent (juvenile-onset; type I) diabetes mellitus. Lancet 1983;1(8339):1397–1399.
  57. Karjalainen J, Knip M, Hyoty H, et al.: Relationship between serum insulin antibodies, islet cell antibodies and Coxsackie-B4 and mumps virus-specific antibodies at the clinical manifestation of Type I (insulin-dependent) diabetes. Diabetologia 1988;31: 146–152.
  58. Pak C, Eun H-M, McArthur R, Yoon J: Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 1988;II:1–4.
  59. Hirata Y, Ishizu H, Ouchi N, et al.: Insulin autoimmunity in a case of spontaneous hypoglycaemia. Journal of the Japan Diabetes Society 1970;13:312–320.
  60. Solimena M, De Camilli P: Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends in Neuroscience 1991;14:452–457.
  61. Flier JS: Lilly Lecture: syndromes of insulin resistance: from patient to gene and back again. Diabetes 1992;41:1207–1219.
  62. Khan C, Baird K, Flier JS, Jarret D: Effects of autoantibodies to the insulin receptor on isolated adipocytes. Studies of insulin binding and insulin action. Journal of Clinical Investigation 1977;60:1094–1106.
  63. Tsokos GC, Gorden P, Antonovych T, et al.: Lupus nephritis and other autoimmune features in patients with diabetes mellitus due to autoantibody to insulin receptors. Annals of Internal Medicine 1985;102:176–181.
  64. Moran A, Brunzell C, Cohen RC, et al.: Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697–2708.
  65. Azzopardi P, Brown AD, Zimmet P, et al.: Type 2 diabetes in young Indigenous Australians in rural and remote areas: diagnosis, screening, management and prevention. Medical Journal of Australia 2012;197:32–36.
  66. Pozzilli P,Guglielmi C:Double diabetes: a mixture of type 1 and type 2 diabetes in youth. Endocrine Development 2009;14:151–166.
  67. Craig ME, Hattersley A, Donaghue KC: Definition, epidemiology and classification. In:Hanas R,Donaghue KC, Klingensmith G, et al. (eds.) Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence. Brussels: International Diabetes Federation, 2011.
  68. Craig ME, Hattersley A, Donaghue KC: Definition, epidemiology and classification of diabetes in children and adolescents. Pediatric Diabetes 2009;10(Suppl 12):3–12.
  69. World Health Organization: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. Geneva: WHO, 2006.
  70. Peterson KP, Pavlovich JG, Goldstein D, et al.: What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization mass spectrometry. Clinical Chemistry 1988;44:1951–1958.
  71. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993;329:977–986.
  72. UKPDS (UK Prospective Diabetes Study Group): Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
  73. Little RR, Rohlfing CL, Sacks DB: Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clinical Chemistry 2011;57:205–214.
  74. Colagiuri S, Lee CM, Wong TY, et al.: Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011;34:145–150.
  75. Khaw KT, Wareham N, Bingham S, et al.: Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Annals of Internal Medicine 2004;141:413–420.
  76. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412.
  77. Sacks DB: A1C versus glucose testing: a comparison. Diabetes Care 2011;34:518–523.
  78. World Health Organization: Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitius. Abbreviated report of a WHO consultation. Geneva: WHO, 2011.
  79. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327–1334.
  80. Christensen DL, Witte DR, Kaduka L, et al.: Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care 2010;33:580–582.
  81. Metzger BE, Lowe LP, Dyer AR, et al.: Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine 2008;358: 1991–2002.
  82. Metzger BE, Gabbe SG, Persson B, et al.: International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676–682.
  83. Santaguida PL, Balion C, Hunt D, et al.: Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence Report/Technology Assessment (Summary) 2005; 1–11.
  84. Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabetic Medicine 2002;19:708–723.
  85. Shaw JE, Zimmet PZ, Hodge AM, et al.: Impaired fasting glucose: how low should it go? Diabetes Care 2000;23:34–39.
  86. Gabir MM, Hanson RL, Dabelea D, et al.: Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000;23:1113–1118.
  87. Ford ES, Zhao G, Li C: Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. Journal of the American College of Cardiology 2010;55:1310–1317.
  88. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–3167.
  89. American Diabetes Association: Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183–1197.